NASDAQ:DXCM - Dexcom Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$100.64 -0.25 (-0.25 %)
(As of 06/19/2018 10:13 AM ET)
Previous Close$100.50
Today's Range$100.50 - $101.69
52-Week Range$42.62 - $102.10
Volume4,876 shs
Average Volume852,092 shs
Market Capitalization$8.78 billion
P/E Ratio-175.18
Dividend YieldN/A
Beta-0.01
Dexcom logoDexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:DXCM
CUSIP25213110
Phone858-200-0200

Debt

Debt-to-Equity Ratio0.79
Current Ratio5.83
Quick Ratio5.42

Price-To-Earnings

Trailing P/E Ratio-175.18
Forward P/E Ratio-197.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$718.50 million
Price / Sales12.34
Cash FlowN/A
Price / CashN/A
Book Value$4.83 per share
Price / Book20.84

Profitability

EPS (Most Recent Fiscal Year)($0.58)
Net Income$-50,200,000.00
Net Margins-4.30%
Return on Equity-9.32%
Return on Assets-4.28%

Miscellaneous

Employees2,990
Outstanding Shares88,080,000

Dexcom (NASDAQ:DXCM) Frequently Asked Questions

What is Dexcom's stock symbol?

Dexcom trades on the NASDAQ under the ticker symbol "DXCM."

How were Dexcom's earnings last quarter?

Dexcom (NASDAQ:DXCM) announced its quarterly earnings data on Wednesday, May, 2nd. The medical device company reported ($0.32) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.32). The medical device company earned $184.40 million during the quarter, compared to analyst estimates of $172.66 million. Dexcom had a negative return on equity of 9.32% and a negative net margin of 4.30%. The business's quarterly revenue was up 29.6% compared to the same quarter last year. During the same period last year, the company posted ($0.49) EPS. View Dexcom's Earnings History.

When is Dexcom's next earnings date?

Dexcom is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Dexcom.

What price target have analysts set for DXCM?

19 equities research analysts have issued 12-month price objectives for Dexcom's shares. Their predictions range from $40.00 to $116.00. On average, they expect Dexcom's stock price to reach $74.50 in the next year. View Analyst Ratings for Dexcom.

Are investors shorting Dexcom?

Dexcom saw a decline in short interest in May. As of May 15th, there was short interest totalling 9,759,794 shares, a decline of 21.3% from the April 30th total of 12,398,444 shares. Based on an average daily volume of 1,605,191 shares, the days-to-cover ratio is presently 6.1 days. Currently, 11.4% of the company's stock are short sold.

Who are some of Dexcom's key competitors?

Who are Dexcom's key executives?

Dexcom's management team includes the folowing people:
  • Mr. Kevin R. Sayer, Chief Exec. Officer, Pres and Director (Age 60)
  • Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 46)
  • Mr. Richard B. Doubleday, Chief Commercial Officer and Exec. VP (Age 55)
  • Mr. Donald M. Abbey, Exec. VP of Quality & Regulatory Affairs (Age 51)
  • Mr. Terrance H. Gregg, Exec. Chairman (Age 69)

Has Dexcom been receiving favorable news coverage?

Media coverage about DXCM stock has been trending somewhat positive this week, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Dexcom earned a media sentiment score of 0.09 on Accern's scale. They also gave news articles about the medical device company an impact score of 48.37 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Dexcom's major shareholders?

Dexcom's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (6.15%), BlackRock Inc. (4.41%), JPMorgan Chase & Co. (2.94%), OppenheimerFunds Inc. (1.70%), Franklin Resources Inc. (1.33%) and Point72 Asset Management L.P. (1.11%). Company insiders that own Dexcom stock include Andrew K Balo, Barbara Kahn, Eric Topol, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for Dexcom.

Which major investors are selling Dexcom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Russell Investments Group Ltd., Massachusetts Financial Services Co. MA, Baillie Gifford & Co., Compagnie Lombard Odier SCmA, Thornburg Investment Management Inc., Allianz Asset Management GmbH and Allianz Asset Management GmbH. Company insiders that have sold Dexcom company stock in the last year include Andrew K Balo, Barbara Kahn, Eric Topol, Jacob Steven Leach, Jay S Skyler, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven Robert Pacelli and Terrance H Gregg. View Insider Buying and Selling for Dexcom.

Which major investors are buying Dexcom stock?

DXCM stock was purchased by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Point72 Asset Management L.P., Neuberger Berman Group LLC, Federated Investors Inc. PA, JPMorgan Chase & Co., Columbus Circle Investors, Frontier Capital Management Co. LLC and Chicago Capital LLC. View Insider Buying and Selling for Dexcom.

How do I buy shares of Dexcom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dexcom's stock price today?

One share of DXCM stock can currently be purchased for approximately $100.89.

How big of a company is Dexcom?

Dexcom has a market capitalization of $8.78 billion and generates $718.50 million in revenue each year. The medical device company earns $-50,200,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Dexcom employs 2,990 workers across the globe.

How can I contact Dexcom?

Dexcom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]


MarketBeat Community Rating for Dexcom (DXCM)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  591 (Vote Outperform)
Underperform Votes:  307 (Vote Underperform)
Total Votes:  898
MarketBeat's community ratings are surveys of what our community members think about Dexcom and other stocks. Vote "Outperform" if you believe DXCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.